己脒 | 5547-54-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 己脒
• 英文名称: n-hexanamidine
• 英文别名: caproamidine；hexanamidine；Hexanamidin；hexanimidamide；hexamidinee
• CAS: 5547-54-6
• 化学式: C₆H₁₄N₂
• 分子量: 114.191
• InChiKey: XZSXCKGIKBUXEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  己脒 在 乙醇 、 氨 、 sodium 作用下， 生成 正己醛
  参考文献：
  名称：

  Birch et al., Chemistry and industry, 1954, p. 1559

  摘要：

  DOI：
• 作为产物：
  描述：

  Hexanimidsaeure-aethylester 在 乙醇 、 ammonium chloride 作用下， 生成 己脒
  参考文献：
  名称：

  Drosdow; Bechli, Zhurnal Obshchei Khimii, 1944, vol. 14, p. 280,290

  摘要：

  DOI：

文献信息

• TRANSITION METAL COMPLEXES OF AMINO ACIDS AND RELATED LIGANDS AND THEIR USE AS CATALYSTS, ANTI-MICROBIALS, AND ANTI-CANCER AGENTS
  申请人：Virginia Tech Intellectual Properties, Inc.

  公开号：US20130096090A1

  公开（公告）日：2013-04-18

  The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few.

  本发明涉及化学和制药领域。本发明实施例提供了氨基酸的过渡金属配合物。根据本发明的实施例的过渡金属配合物可用作抗微生物、抗疟疾和抗癌剂，以及化学反应中的催化剂。本发明的这类化合物特别适用于对抗广泛范围微生物（如MRSA和分枝杆菌）的多药耐药性，包括革兰氏阳性和革兰氏阴性细菌，也可用作抗癌剂对抗膀胱癌、乳腺癌、结肠癌、直肠癌、子宫内膜癌、肾癌、白血病、肺癌、黑色素瘤、非霍奇金淋巴瘤、胰腺癌、前列腺癌和甲状腺癌等。
• Fused Pyrazoles as FGFR Inhibitors
  申请人：Incyte Corporation

  公开号：US20140171405A1

  公开（公告）日：2014-06-19

  The present invention relates to fused pyrazole derivatives, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

  本发明涉及融合吡唑衍生物，以及包括这些衍生物的药物组合物，这些衍生物是一种或多种FGFR酶的抑制剂，并且在治疗FGFR相关疾病如癌症方面具有用处。
• META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS
  申请人：Steinmetzer Torsten

  公开号：US20100305090A1

  公开（公告）日：2010-12-02

  The invention relates to meta-substituted phenyl sulfonyl amides of secondary amino acid amides according to the general formula (I), (II), or (III), the production thereof, and the use thereof as matriptase inhibitors, in particular the use thereof as drugs for inhibiting tumor growth and/or metastasization.

  该发明涉及通式（I）、（II）或（III）的次级氨基酸酰胺的亚苯基磺酰胺，其制备方法以及其作为matriptase抑制剂的用途，特别是其作为抑制肿瘤生长和/或转移的药物的用途。
• [EN] OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] COMPOSÉS OXADIAZOLE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011104680A1

  公开（公告）日：2011-09-01

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及氧代唑化合物的所有立体异构体和互变异构体形式以及它们在所有比例的混合物中；以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多形态。该发明还涉及制备氧代唑化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物可用于治疗癌症，特别是慢性髓样白血病（CML）。本发明还提供了一种治疗癌症的方法，即通过向需要的哺乳动物投予所述化合物或其药物组合物的治疗有效剂量。
• Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use
  申请人：Moore, II Bob M.

  公开号：US20090286815A1

  公开（公告）日：2009-11-19

  Disclosed are compounds of the formula I: wherein R 1 , R 2 , V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.

  揭示的是公式I的化合物：其中R1、R2、V、W、X、Y和Z可以如本文所定义。这些化合物可用于治疗由大麻素受体介导的疾病。